218 related articles for article (PubMed ID: 34079282)
1. Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.
Cheng Q; Wang J; Lv C; Xu J
Onco Targets Ther; 2021; 14():3367-3372. PubMed ID: 34079282
[TBL] [Abstract][Full Text] [Related]
2. Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases.
Liu Y; Sun J; Tuo K
Case Rep Oncol; 2023; 16(1):227-233. PubMed ID: 37069896
[TBL] [Abstract][Full Text] [Related]
3. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
Yuan X; Li X; Huang Y; Jin X; Liu H; Zhao A; Zhang W; Qian W; Liang Y
Front Immunol; 2022; 13():1015081. PubMed ID: 36505470
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy.
Wang N; Chen FL; Pan L; Teng Y; Wei XJ; Guo HG; Jiang XM; Huang L; Liu SC; Liang ZL; Li WY
World J Clin Oncol; 2023 Dec; 14(12):606-619. PubMed ID: 38179402
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
[TBL] [Abstract][Full Text] [Related]
7. BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report.
Feng L; Gao X; Jiao Z; Wang Z; Min F
Oncol Lett; 2023 Feb; 25(2):48. PubMed ID: 36644138
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
9. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
10. Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.
Zhang Y; Li Y; Zhuang Z; Wang W; Wei C; Zhao D; Zhou D; Zhang W
Front Oncol; 2021; 11():760405. PubMed ID: 35004280
[TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
Steffanoni S; Batchelor TT
Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
13. Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Wang L; Guan W; Peng X
Front Oncol; 2021; 11():676792. PubMed ID: 33968786
[TBL] [Abstract][Full Text] [Related]
14. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
15. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
17. Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review.
Alsuhebany N; Pan C; Holovac E; Do B; McBride A
Blood Lymphat Cancer; 2023; 13():67-76. PubMed ID: 38034984
[TBL] [Abstract][Full Text] [Related]
18. Zanubrutinib plus cytarabine in patients with refractory/relapsed primary central nervous system lymphoma.
Lin Z; Ma J; Ma Y; Li Q; Kang H; Zhang M; Chen B
Acta Haematol; 2024 Feb; ():. PubMed ID: 38408440
[TBL] [Abstract][Full Text] [Related]
19. Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of
Xing L; Wang H; Liu D; He Q; Li Z
Front Oncol; 2022; 12():1079890. PubMed ID: 36741708
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
Shen J; Liu J
Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
